The Latest Cardiac and Vascular News
Additional FOURIER Analysis Shows Lowering LDL-C With Repatha Did Not Impair Patient-Reported Cognition THOUSAND OAKS, Calif., Nov. 16, 2019 /PRNewswire/ — Amgen today announced a new analysis from the Repatha® (evolocumab) cardiovascular outcomes (FOURIER) study that evaluates the effectiveness of Repatha in patients who have suffered a recent myocardial infarction (MI). The analysis showed […]
New Registry, cvMOBIUS, Will Assess Lipid Therapies and Five-Year Cardiovascular Outcomes in 8,500 High-Risk Patients With a Recent Atherosclerotic Cardiovascular Disease Event THOUSAND OAKS, Calif., Nov. 15, 2019 /PRNewswire/ — Amgen (NASDAQ:AMGN) in collaboration with the Duke Clinical Research Institute (DCRI) today announced plans to initiate the Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 inhibitors […]
SAN FRANCISCO, June 25, 2019 /PRNewswire/ — Amgen (NASDAQ:AMGN) and MBC BioLabs (formerly QB3@953) today announced that Regencor and Nitrome Biosciences have each been awarded an Amgen Golden Ticket to MBC BioLabs. The companies receive priority admission or renewal for one year of lab bench space and access to core facilities at the MBC BioLabs […]
ATLANTA, April 17, 2019 /PRNewswire/ — According to the World Health Organization (WHO), cardiovascular disease (CVD) is the leading cause of death worldwide, responsible for nearly 18 million deaths in 2016 alone. More than three-quarters of these deaths occur in low- and middle-income countries. To increase understanding of this globally important issue, […]
THOUSAND OAKS, Calif., March 6, 2019 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the presentation of nine cardiovascular scientific research abstracts, including safety and efficacy results from the largest and longest open label study of homozygous familial hypercholesterolemia (HoFH) patients (TAUSSIG),1 as well as a sub-analysis from the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER). Additional abstracts […]
THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the National Medical Products Administration (NMPA) has approved a new indication for Repatha® (evolocumab) as the first PCSK9 inhibitor in China for adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of myocardial infarction, stroke and coronary revascularization. Low-density lipoprotein cholesterol […]
THOUSAND OAKS, Calif., Jan. 7, 2019 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that as part of the Company’s commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, all Repatha® (evolocumab) device options, including the Pre-Filled Syringe and Pushtronex® (on-body infusor […]
PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $10 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a clinical study. Amgen is evaluating AMG 890 in a Phase 1 clinical study […]
THOUSAND OAKS, Calif., May 16, 2018 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels. With the […]
THOUSAND OAKS, Calif., Dec. 1, 2017 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that following priority review of its supplemental Biologics License Application, the U.S. Food and Drug Administration (FDA) approved Repatha® (evolocumab) as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularizations in adults with established cardiovascular disease.1 “We are pleased […]
